Sep 8, 2026 07:50AM
Sep 8, 2026 07:50AM
May 27, 2026 04:04AM
Mar 9, 2026 08:45AM
Mar 9, 2026 07:00AM
Mar 9, 2026 02:30AM
Feb 3, 2026 07:00AM FDA grants Priority Review to DATROWAY for metastatic triple-negative breast cancer
Feb 3, 2026 07:00AM
Feb 3, 2026 04:11AM
Feb 3, 2026 02:30AM
Dec 2, 2025 09:18AM
Dec 2, 2025 09:18AM
Oct 1, 2025 07:00AM
Oct 1, 2025 07:00AM ENHERTU® Followed by THP Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk HER2 Positive Early-Stage Breast Cancer Prior to Surgery
Sep 24, 2025 07:00AM
Sep 24, 2025 02:30AM
Jul 28, 2025 07:01AM
Jul 28, 2025 07:00AM
Jan 13, 2025 07:00AM
Jan 13, 2025 06:09AM
Jan 13, 2025 02:00AM Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Dec 11, 2024 09:44AM
Dec 6, 2024 07:00AM
Dec 6, 2024 06:14AM
Oct 3, 2024 07:04AM
Oct 3, 2024 07:00AM
Oct 3, 2024 06:11AM
Oct 1, 2024 07:06AM AstraZeneca (AZN): ENHERTU granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer
Oct 1, 2024 07:00AM
Oct 1, 2024 06:19AM
Oct 1, 2024 02:00AM
Sep 13, 2024 04:00AM
Aug 15, 2024 07:02AM
Aug 15, 2024 07:00AM
Jun 10, 2024 07:00AM TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
Jun 10, 2024 06:03AM
Jun 10, 2024 04:36AM
Apr 2, 2024 07:00AM
Apr 2, 2024 05:36AM
Apr 2, 2024 02:00AM
Feb 19, 2024 07:10AM
Feb 19, 2024 02:00AM Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Jan 29, 2024 07:00AM
Jan 29, 2024 06:00AM
Jan 29, 2024 02:00AM
Oct 24, 2023 07:00AM
Oct 24, 2023 05:46AM
Oct 16, 2023 07:00AM
Oct 16, 2023 06:16AM AstraZeneca (AZN) reports Tagrisso plus chemotherapy granted Priority Review in the US
Jul 28, 2023 07:05AM

15,781 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All